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Summary: This study describes the value of using the fraction of free prostate-specific antigen as a further marker
in the early detection of prostate cancer. This newly introduced marker is compared to the usual battery of age-
dependent total prostate-specific antigen, prostate-specific antigen density (μ^Ι Χ g tissue) and prostate-specific
antigen velocity ^g/l X year).
Determination of total prostate-specific antigen and free prostate-specific antigen was performed on fresh serum
samples obtained from 3470 symptomatic patients aged 45—80 attending the Urology Clinics, or their General
Practitioners. Among them, 310 patients had total prostate-specific antigen above the age-dependent cut-off, and/or
free/total prostate-specific antigen under 11%, with different prostate-specific antigen densities and velocities. Only
147 patients complied to undergo biopsy: in 72 of those patients, benign prostatic disease was histologically con-
firmed, while in 75 patients primary prostate cancer was histologically confirmed. Total and free prostate-specific
antigen levels were determined using the third generation DPCs prostate-specific antigen assay performed on the
Immulite automated immunoassay instrument. Total prostate-specific antigen age reference values were adopted
from Oesterling et al. (J Am Med Ass 1993; 270:860—4); the prostate-specific antigen density was considered
suspicious of prostate cancer if it was greater than 0.15 μg/l prostate-specific antigen per gram tissue (Seaman et
al. Urol Clin N Am 1993; 20:653); prostate-specific antigen velocity greater than 0.75 μg/l X year (Carter et al., J
Am Med Ass 1992; 267:215) was considered suspicious for prostate cancer.
Of the 147 patients, 75 had prostate cancer and 72 had benign prostatic hypertrophy. The difference between
prostate cancer and benign prostatic hypertrophy was significantly reflected only by free/total prostate-specific
antigen and prostate-specific antigen velocity. These parameters also provided the best sensitivity and specificity.
Only these parameters proved to be significant when using a backwards logistic regression model (prostate-specific
antigen velocity, p = 0.007 odds ratio 2.782; free/total prostate-specific antigen %, p = 0.016 odds ratio 2.678).
Combinations of various parameters became significant when including free/total prostate-specific antigen, increas-
ing prostate cancer detection to 88%.
We conclude that free/total prostate-specific antigen is the most significant among prostate-specific antigen quanti-
ties (total age-dependent prostate-specific antigen, prostate-specific antigen density and prostate-specific antigen
velocity). Adding this parameter to other prostate-specific antigen parameters improves the discrimination between
prostate cancer and benign prostatic hypertrophy for the population at risk.
Introduction
The benefit of early detection of prostate cancer is con- sound and needle biopsy have prostate-specific antigen
troversial (2—6). However, until appropriate studies are concentrations above the cut-off values used (7—11).
conducted to determine the population at risk and on the Prostate-specific antigen alone will miss 38—48% of or-
individual level the patient who will benefit from early gan-confined but clinically significant prostate cancer
detection, clinicians are obligated to provide the patient (12—13). On the other hand, approximately only one in
with all possible modes of diagnosis and treatment, to- four men with prostate-specific antigen above 4 μg/l will
gether with the basic knowledge on the natural history have a prostate cancer (8, 9, 11, 14). The detection of
of the disease. The use of prostate-specific antigen as a prostatic cancer in its curable stages requires the use of
tool in the diagnosis of prostate cancer has gained wide relatively low prostate-specific antigen cut-off, since
acceptance because about 70% of patients with cancers low cut-offs render high false positive rates, leading to
identified by digital rectal examination, transrectal ultra- unnecessary biopsies. Prostate-specific antigen density
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(15 — 17), prostate-specific antigen velocity (18, 19) and
prostate-specific antigen age-specific reference ranges
(1,20—22) were introduced in order to improve the clin-
ical use of prostate-specific antigen for early detection
of prostate cancer. Another potential way for refinement
of the prostate-specific antigen assay was the introduc-
tion of the free prostate-specific antigen test. Several in-
vestigators have demonstrated that prostate-specific an-
tigen is complexed (in vitro) to the protease inhibitors
ai-antichymotrypsin and aa-macroglobulin (23—25):
the commercial assays for prostate-specific antigen mea-
sure complexed as well as free prostate-specific antigen,
and most of them are claimed to measure equimolar
quantities of both (26). The proportion of free prostate-
specific antigen is lower in prostate cancer than in be-
nign prostatic hypertrophy and the free/total prostate-
specific antigen ratio can distinguish better between
prostate cancer and benign prostatic hypertrophy
(27—31). In this study we measured the free/total pros-
tate-specific antigen and correlated it to the battery con-
sisting of age-adjusted total prostate-specific antigen,
prostate-specific antigen density and prostate-specific
antigen velocity usually used in our laboratory for detec-
tion of prostate cancer.
Number of study participants with symptoms: 3470
(Prostatitis, urinary infections, prostate manipulations ruled out)
Prostate-specific antigen
Total (age adjusted) and/or Free/Total (%)
ι Abnormal -+· Normal 3160/3470
310/3470(8.9%)
offered digital rectal examination,
trans-rectal ultrasound + biopsy
underwent digital rectal examination,





Fig. 1 Patients flow chart. The initial study comprised 3470
symptomatic patients (any previous non-related prostatic or urinary
disease or manipulation was ruled out). Threehundred-ten of them
had abnormal age-related total prostate-specific antigen and/or ab-
normal free/total prostate-specific antigen and were offered further
evaluation. Hundred-fourty seven patients underwent digital rectal
examination, trans-rectal ultrasound and prostate biopsies (core).
Seventy-five patients had prostate cancer and 72 had benign pros-
tatic hypertrophy by histological findings.
tests and expressed as the prostate-specific antigen increment per
year. Prostate-specific antigen velocity higher than 0.75 μ^ Χ
year was suspicious for prostate cancer (18). In several cases, a
negative velocity was recorded. If several prostate-specific antigen
tests were performed during the previous year, a mean value of
prostate-specific antigen velocity was calculated.
Materials and Methods
Subjects and procedures
From February 1995 through December 1995, we measured prospec-
tively total prostate-specific antigen and free prostate-specific anti-
gen concentrations in 3470 men aged 45 to 80 years (67.3 ± 7.5
years, mean ± S. D.). All these patients complained of benign pros-
tatic hypertrophy-related urinary symptoms (nocturia, hesitancy, in-
complete voiding sensation, etc.). Patients with a previous history of
prostate cancer, prostatitis or urinary infections were excluded.
Blood was drawn prior to the digital rectal examination and transfer-
red promptly to the laboratory. After 30 minutes at room temperature,
the samples were centrifuged for 10 minutes at 1500g, the serum
was removed and assayed for both total and free prostate-specific
antigen. In a pilot study performed on 100 men using a ROC
(receiver operating characteristic) curve analysis, we found a cut-off
value of 11% for free/total prostate-specific antigen (see Results) to
give best discrimination between benign prostatic hypertrophy and
prostate cancer. Of the 310 patients having prostate-specific antigen
levels higher than the age-related cut-off or those having free/total
prostate-specific antigen lower than 11% were asked to repeat both
tests within one month. Of these, 147 patients having repeated posi-
tive tests were referred to our institute for further evaluation. They
underwent digital rectal examination and prostatic trans-rectal ultra-
sound (see flow chart, fig. 1). The age reference prostate-specific an-
tigen concentrations used were:
:S 49 years — prostate-specific antigen ^ 2.5 μ§/1,
^ 59 years - prostate-specific antigen < 3.5 μg/l,
^ 69 years — prostate-specific antigen ^ 4.5 μg/l,
s 79 years — prostate-specific antigen ^ 6.5 μ^.
Prostate-specific antigen density was calculated by dividing the to-
tal prostate-specific antigen level by the prostate volume, which
was calculated via the prolate spheroid formula using the trans-
rectal ultrasound scan (32). A density higher than 0.15 μg/l X g
(17) was considered suspicious for prostate cancer. Prostate-spe-
cific antigen velocity was calculated by dividing the difference be-
tween two consecutive prostate-specific antigen determinations
performed during 3 to 12 months divided by the period between
Immunoassays
Total and free prostate-specific antigen were measured using DPCs
(Diagnostic Products Corporation, Los Angeles, CA) chemilumi-
nescent enzyme immunoassays with the Immulite immunoana-
lyzer. Both DPC prostate-specific antigen tests are claimed to be
in good agreement with Stanford International Standard by its man-
ufacturer (33). Briefly, the Immulite prostate-specific antigen is a
solid-phase, two-site chemiluminescent enzyme immunometric as-
say using a polyclonal anti-prostate-specific antigen as the capture
antibody and a conjugated monoclonal as the detector antibody.
The test's working range is 0.04—150 μg/l.
The Immulite free prostate-specific antigen assay makes use of a
monoclonal antibody specific for epitopes on prostate-specific anti-
gen that are rendered inaccessible by complex formation between
prostate-specific antigen and ai-antichymotrypsin as the capture
antibody and a labelled polyclonal goat anti-prostate-specific anti-
gen as the detector antibody. The free prostate-specific antigen as-
say has a working range of 0.05—100 μg/l.
Both tests have good performance profiles as stated by the manu-
facturer and are monitored daily in our laboratory by internal and
external quality control programmes. The inter- and intra-assay
CV% were 3.6% and 5.7% for total prostate-specific antigen and
3.5% and 6.0% for free prostate-specific antigen. The ratio of free/-
total prostate-specific antigen was calculated by dividing the free
prostate-specific antigen duplicates mean value by the total pros-
tate-specific antigen duplicates mean value and multiplied by 100.
Statistical analysis
Wilcoxon (a non-parametric statistical test) was used to assess the
statistical significance of differences in the values of total prostate-
specific antigen and free/total prostate-specific antigen between be-
nign prostatic hypertrophy and prostate cancer patients. (Receiver-
operating characteristic (ROC) curves were generated by plotting
sensitivity versus specificity to evaluate the free/total prostate-spe-
cific antigen assay performance.) Sensitivity, specificity, positive
predictive value and negative predictive value were calculated for
each parameter (total prostate-specific antigen, free/total prostate-
specific antigen, prostate-specific antigen density, prostate-specific
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antigen velocity). Chi square statistical test was performed on each
of the parameters against the benign/malignant diagnosis constant.
Sensitivity, specificity and accuracy of combinations of different
parameters were also calculated. A model of backwards logistic
regression was applied in order to assess the relative weight of
each of the parameters, while in each step the model eliminates the
less significant parameter. The odds ratio represents the chances of
having prostate cancer among the patients with positive tests, ver-
sus those with normal tests.
Results
We measured total and free prostate-specific antigen and
calculated the proportion of free/total prostate-specific
antigen in 3470 men aged 45—80. In our institute only
147 men underwent prostate digital rectal examination,
trans-rectal ultrasound guided, or 6 sextants systematic
sampling of core biopsies of the prostate. Seventy-five
of them indeed had biopsy-proven prostate cancer.
Based on a previous pilot study (data unpublished),
which calculated the sensitivity and specificity of free/-
total prostate-specific antigen at different cut-off levels,
we plotted the ROC curve (fig. 2). The optimal cut-off
point was found to be 11% with a sensitivity of 81%
and a specificity of 43%. A scattergram of the results is
shown in figure 3.
Total prostate-specific antigen, free/total prostate-spe-
cific antigen, prostate-specific antigen velocity and pros-
tate-specific antigen density are summarized for these
patients in table 1. The frequency of abnormal results is
presented in tables 2a and 2b.
Table 3 shows the sensitivities and specificities of each
of the prostate-specific antigen parameters at the pre-
viously assigned cut-offs. Table 3 also adds the positive
and negative predictive values, as well as the P value of
each of the prostate-specific antigen parameters.
Table 4a shows the estimated sensitivity, specificity and
accuracy of combinations of the different prostate-spe-
cific antigen parameters, accomplished by using a back-
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Fig. 2 Free/total prostate-specific antigen. Receiver operating
characteristics analysis represents the sensitivity (%) and 1-speci-
ficity (%) of the test at different cut-off points. Points represent
the different cut-offs (5 μ^ to 21 μg/l) at which sensitivities and
specificities were calculated.
Tab. 1 Prostate-specific antigen parameters (age dependent total
prostate-specific antigen, free/total prostate-specific antigen, pros-
tate-specific antigen velocity and prostate-specific antigen density)
are represented by their mean, median and standard deviation,
























SD 7.19 5.43 0.001*
Prostate-specific antigen
velocity ^g/l X year)
Mean 11.68 21.78
Median 3.7 9.90 0.055
SD 20.57 50.74
Prostate-specific antigen
density ^g/l X g)
Mean 0.34 1.27
Median 0.26 0.36 0.001*
SD 0.30 3.95
ward logistic regression model. This model predicts the
relative importance of each parameter. The model begins
the evaluation with all parameters and eliminates in each
step the quantity with the least significant contribution
to the chi square, leaving eventually only the significant
parameter. The results of the logistic regression are pre-
sented in table 4b. These results show the different pros-
tate-specific antigen quantities by the order of their sig-
nificance. Prostate-specific antigen density and total
prostate-specific antigen were not significant and there-
fore have been withdrawn.
Figure 4 enables some observations regarding the capa-
bilities of different parameter combinations. It is worth
noting how misleading it could be to rely solely on posi-
tive total prostate-specific antigen and prostate-specific
antigen density in predicting prostate cancer. It also
shows the diagnostic improvement achieved by adding
more parameter results. The figure shows that using all
four parameters (adding free/total prostate-specific anti-
gen to the total+velocity+density) increases the amount
of prostate cancer patients by almost fivefold, while
increasing a "wrongly" detected benign prostatic hyper-
trophy patient by 2.3-fold.
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Tab. 2a The fraction of the abnormal results among all the 147 patients and its distribution in the
benign prostatic hypertrophy and prostate cancer populations, in each of the prostate-specific
antigen parameters.
Total fraction of abnormal results (%)



















hypertrophy patients only (%)








Tab. 2b Focus on the interaction of total and free/total prostate-specific antigen results. The parenthesis









Tab. 3 Sensitivity, specificity, positive predictive value, negative predictive value and P value
(Chi square test) for each of the 4 prostate-specific antigen parameters.




































Tab. 4a Predicted sensitivity, specificity, accuracy and significance (P value) of various prostate-specific
antigen parameter combinations achieved by using a backward logistic regression model.
Prostrate-specific antigen tests combined Sensitivity Specificity Accuracy P value
Al Free/total Velocity Density
+ + + + 62.3
+ + + 63.9
+ - + + 70.49
+ + - + 79.41
+ + - - 79.41
- + + - 54.1






















Tab. 4b First and final steps of the logistic regression represented by P value and odds ratio of the
examined parameters.
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Fig. 3 A scattergram of all patients included in the study, free/to-
tal prostate-specific antigen is depicted as a function of the total










Total + variant Total + free
+ density + variant + density
Fig. 4 Fraction of patients having positive prostate-specific anti-
gen parameter combinations. The figure focuses on only three ex-
amples of combinations for reasons of simplifying the interpreta-
tion of the results.
Discussion
In the last three years there has been a significant
increase in the general use of prostate-specific antigen
by urologists and general practitioners. Today an abnor-
mal prostate-specific antigen is probably the first step in
the primary detection of prostate cancer in most of the
prostate cancer patients. The considerably high rate of
false-positive total prostate-specific antigen values led
to the addition of prostate-specific antigen density and
prostate-specific antigen velocity to the protocols of
early prostate cancer detection in more recent works
(15-19). In view of data indicating that free/total pros-
tate-specific antigen enhances the specificity of the pros-
tate-specific antigen test, it was added in the last four
years to the battery of prostate-specific antigen parame-
ters. Most of the studies concerning free/total prostate-
specific antigen were performed retrospectively on
stored sera of patients already diagnosed. The fact that
free prostate-specific antigen was measured later than
total prostate-specific antigen and/or later than the time
of taking the fresh blood sample is even more significant
in view of the data regarding the relative instability of
the prostate-specific antigen-α i-antichymotrypsin com-
plex (38, 39). In our study, total prostate-specific antigen
and free prostate-specific antigen were performed simul-
taneously on fresh blood samples, using one instrument,
and kits of the same manufacturer.
Our goal in this study was to improve the accuracy of
prostate-specific antigen for early detection of prostate
cancer in patients with symptomatic prostatic disease.
If prostate-specific antigen, with its various parameters,
regardless and prior to using the other means for prostate
cancer detection (digital rectal examination, trans-rectal
ultrasound, biopsy, etc.), could render good diagnostic
results it would mean saving and avoiding expensive
and invasive and often unnecessary tests.
All the participants in our study had abnormal prostate-
specific antigen values, either abnormal age-adjusted to-
tal prostate-specific antigen or abnormal free/total pros-
tate-specific antigen: these were the inclusion criteria.
Because of ethical reasons, patients with normal results
were not offered a further investigative diagnostic pro-
cedure. The cut-off limit for free/total prostate-specific
antigen was chosen to be 11% (free/total prostate-spe-
cific antigen < 11% indicative of cancer). This is based
on our ROC curve (fig. 2) and is in agreement with
Blankenstein's study (40) that uses the same kits and
reached the same cut-off value. Our 11% cut-off value
is lower than Oesterling's (29) or Christensson's 18%
(41), it therefore may enhance the specificity while
lowering the sensitivity. The lower cut-off value is pos-
sibly due to a different calibration of the different kits
as both in Blankenstein's and in our studies, different
kits from those of Oesterling's and Christensson's were
used. Recent data from another manufacturer (Boeh-
ringer-Mannheim) using their kits also indicate that the
cut-off level should be 14% and not 18% (data on file
— Boehringer-Mannheim).
Our inclusion criteria are clearly reflected by the fre-
quency of abnormal marker results among the 147 ex-
aminees (tab. 2). It is clear that total prostate-specific
antigen and prostate-specific antigen density are abnor-
mal to the same extent and different than both free/total
prostate-specific antigen and prostate-specific antigen
velocity. These data correlate with various studies that
demonstrated resemblance in the performance of the to-
tal prostate-specific antigen and prostate-specific anti-
gen density. The high percentage of abnormal tests of
total prostate-specific antigen and prostate-specific anti-
gen density among all the 147 patients reflects a rela-
tively high percentage of pathological results in the be-
nign prostatic hypertrophy group in addition to the pros-
tate cancer group. These data explain the low diagnostic
accuracy of total prostate-specific antigen and prostate-
specific antigen density as shown in our results. Table 2b
shows the distribution of total prostate-specific antigen
positives and free/total prostate-specific antigen posi-
tives and how many of these had prostate cancer (and
ignores the other quantities which were examined,
namely the prostate-specific antigen velocity and the
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prostate-specific antigen density). It is important to note
the diagnostic benefit of the free/total prostate-specific
antigen over the total prostate-specific antigen, espe-
cially when considering the fact that these two tests
would be, in most cases, the first step in the diagnostic
work-up of a patient with prostate-related symptoms.
When each of the parameters (total prostate-specific an-
tigen, free/total prostate-specific antigen, prostate-spe-
cific antigen density, prostate-specific antigen velocity)
was examined separately, only free/total prostate-spe-
cific antigen and prostate-specific antigen velocity were
statistically significant in detection of prostate cancer vs.
benign prostatic hypertrophy, P value < 0.05 (tab. 3).
The inability of total prostate-specific antigen and pros-
tate-specific antigen density to prove significance in de-
tecting prostate cancer in contrast to benign prostatic
hypertrophy does not undermine its value in detecting
prostatic disease among normal patients, as shown in
many studies. The latter two parameters failed, however,
to prove significance in the given situation of an abnor-
mal prostate-specific antigen test.
When logistic regression was performed (e. g. all four
parameters are taken and then omitted one after the
other if they fail to show significance, leaving only
the significant parameters), a combination of free/total
prostate-specific antigen and prostate-specific antigen
velocity was reached. This combination has in fact a
better P value than any other single parameter or
combination of parameters (tab. 4a). Another indica-
tion of the power of the free/total prostate-specific
antigen and the prostate-specific antigen velocity com-
bination can be found in the odds ratio calculation
(tab. 4b), which shows a clear advantage of free/total
prostate-specific antigen and prostate-specific antigen
velocity over total prostate-specific antigen and pros-
tate-specific antigen density.
As a single parameter, free/total prostate-specific antigen
had the best P value (0.0013). Free/total prostate-spe-
cific antigen had the best sensitivity (81%), better than
any single or combination of parameters.
Various other combinations, if only including either
free/total prostate-specific antigen or prostate-specific
antigen velocity, became also significant (tab. 4a). There
is, in fact, no significant statistical difference between
the P values or the accuracies of the various combina-
tions in table 4a. The more substantial differences be-
tween these various combinations are different sensitiv-
ity, specificity and odds ratios.
The additional value of adding free/total prostate-spe-
cific antigen to the battery of total prostate-specific anti-
gen, prostate-specific antigen density and prostate-spe-
cific antigen velocity is shown in figure 4. When adding
free/total prostate-specific antigen to the other three
parameters the percentage of the prostate cancer patients
increases (from 8.7% to 42%), yet the "price" is dou-
bling the amount of benign prostatic hypertrophy ("false
positive" cases from 7.6% to 18.2%). We claim that
when dealing with a population at risk, the meaning of
higher rates of early detection of prostate cancer is of
greater importance than the cost and risk of the digital
rectal examination, trans-rectal ultrasound and biopsy
that would eventually be performed on benign prostatic
hypertrophy patients.
We used the results of the core biopsies under trans-
rectal ultrasound as our gold standard for detecting and
establishing the diagnosis of prostate cancer vs. benign
prostatic hypertrophy. It is reasonable to assume that
there is a considerable amount of false negatives in these
biopsies, and that a repeated biopsy taken after some
time or a trans-urethral resection of prostate, prostatec-
tomy or radical prostatectomy, would reveal more fo-
cuses of prostate cancer (with the latter being truly the
gold standard for histologic diagnosis). The question
whether such a bias is actually only for the best due to
the latent nature and slow progression of the prostate
cancer is still valid.
We propose an algorithm based on our findings and on
clinical and practical considerations (fig. 5) for the use
of the various prostate-specific antigen parameters in the
early detection of prostate cancer. There is a need for
ample further prospective studies incorporating this al-
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Fig. 5 Proposed algorithm for the use of prostate specific antigen
parameters in early detection of prostate cancer. Each patient
should undergo a yearly age-dependent total prostate-specific anti-
gen examination. If abnormal, then total (* — second time) and
free prostate-specific antigen should be performed. If one of the
two parameters is abnormal then trans-rectal ultrasound is required
and is followed by biopsy if abnormal. If both total and free/total
prostate-specific antigen are normal another (third) total prostate-
specific antigen test is done to achieve the prostate-specific antigen
velocity. If normal, a 6-monthly repeated follow up is offered. If
the prostate-specific antigen velocity is abnormal trans-rectal ultra-
sound is required and is again followed by biopsy if abnormal, or
only by a 6-monthly follow-up if normal.
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